pramipexole

(redirected from Mirapex ER)
Also found in: Dictionary.

pramipexole

 [pram″ĭ-pek´sōl]
a dopamine agonist used in the form of the dihydrochloride salt in treatment of parkinson's disease, administered orally.

pramipexole

/pram·i·pex·ole/ (pram″ĭ-pek´sōl) a dopamine agonist used in the form of the dihydrochloride salt as an antidyskinetic in the treatment of Parkinson's disease.

pramipexole

(prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

pramipexole

an antiparkinson agent.
indication It is used to treat parkinsonism.
contraindication Known hypersensitivity prohibits its use.
adverse effects Life-threatening effects are hemolytic anemia, leukopenia, and agranulocytosis. Other adverse effects include psychosis, hallucination, depression, dizziness, constipation, impotence, and blurred vision. Common side effects include agitation, insomnia, nausea, anorexia, and orthostatic hypotension.

pramipexole

Mirapex® Neurology A dopamine antagonist used to manage Parkinson's disease Adverse effects Constipation, dry mouth, vision defects, insomnia
References in periodicals archive ?
According to IMS Health, the MIRAPEX ER brand and generic had US sales of about USD48.
Azilect, along with levodopa and the dopamine agonists pramipexole (Boehringer Ingelheim's Mirapex ER, Mirapex, generics) and ropinirole (GlaxoSmithKline's Requip XL, Requip, generics) are mainstay treatments in the Parkinson's disease treatment algorithm, with the three-times-daily formulations of the dopamine agonists experiencing greater use among recently treated patients than their once-daily counterparts, according to claims data analysis.
GlaxoSmithKline's Requip XL, for example, showed relatively constant first-line therapy use among newly diagnosed patients and Boehringer Ingelheim's Mirapex ER has seen its patient share increase among the same patient population.